Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $41.10.

A number of research analysts have commented on KYMR shares. Stifel Nicolaus upped their price target on Kymera Therapeutics from $35.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Oppenheimer decreased their target price on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Truist Financial increased their target price on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. increased their target price on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Wolfe Research began coverage on Kymera Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company.

Kymera Therapeutics Price Performance

KYMR opened at $35.70 on Friday. The business has a 50 day simple moving average of $36.99 and a two-hundred day simple moving average of $31.71. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -14.22 and a beta of 2.31. Kymera Therapeutics has a one year low of $9.60 and a one year high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. The business had revenue of $10.30 million during the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. Kymera Therapeutics’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.70) EPS. As a group, sell-side analysts expect that Kymera Therapeutics will post -2.86 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Bruce Booth sold 71,764 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares in the company, valued at approximately $32,638,960.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Bruce Booth sold 71,764 shares of Kymera Therapeutics stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares in the company, valued at $32,638,960.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $1,812,640.70. Following the transaction, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The disclosure for this sale can be found here. Insiders have sold a total of 423,529 shares of company stock worth $17,815,113 in the last ninety days. Insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. Virtu Financial LLC bought a new stake in Kymera Therapeutics during the first quarter valued at about $207,000. Artal Group S.A. raised its holdings in Kymera Therapeutics by 19.6% during the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after acquiring an additional 496,400 shares during the period. Comerica Bank raised its holdings in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares during the period. California State Teachers Retirement System raised its holdings in Kymera Therapeutics by 5.5% during the first quarter. California State Teachers Retirement System now owns 40,423 shares of the company’s stock valued at $1,625,000 after acquiring an additional 2,102 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in Kymera Therapeutics during the first quarter valued at about $569,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.